FMR1NB Involved in Glioma Tumorigenesis Is a Promising Target for Prognosis and Therapy

Abstract

Objective

Cancer/testis antigen FMR1NB is aberrantly expressed in various types of cancer, but not in normal tissues except for testis. This study aimed to investigate the expression and functional role of FMR1NB in glioma.

Methods

The expression of FMR1NB mRNA and protein was determined using RT-PCR and immunohistochemistry, respectively, in glioma specimens from 83 patients at follow-up. The effects of siRNA-mediated FMR1NB silencing on malignant biological behaviors were evaluated in glioma cell lines A172 and U251.

Results

FMR1NB mRNA and protein expression was detected in 58.8% (77/131) and 46.34% (57/123) of glioma tissues, respectively. FMR1NB protein was positively correlated with World Health Organization grade and found to be an independent prognostic marker for poor outcome. Knockdown of FMR1NB induced apoptosis and suppressed proliferation, adhesion, migration, and invasion by modulating the expression of cyclin A, CDK2, caspase-3, E-cadherin, and N-cadherin in A172 and U251 cells.

Conclusion

Our findings suggest that FMR1NB contributes to the tumorigenesis of glioma cells and may represent a potential prognostic biomarker and an attractive therapeutic target in glioma.

Keywords

cancer/testis antigen / FMR1NB / glioma

References

[1] OstromQT, GittlemanH, LiaoP, et al.. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014. Neuro Oncology, 2017, 19(suppl_5): v1-v88

[2] YangP, WangY, PengX, et al.. Management and survival rates in patients with glioma in China (2004–2010): a retrospective study from a single-institution. J Neurooncol, 2013, 113(2): 259-266

[3] WangHW, XuZK, SongY, et al.. Correlations of MGMT genetic polymorphisms with temozolomide resistance and prognosis of patients with malignant gliomas: a population-based study in China. Cancer Gene Ther, 2017, 24(5): 215-220

[4] LiK, LuD, GuoY, et al.. Trends and patterns of incidence of diffuse glioma in adults in the United States, 1973–2014. Cancer Med, 2018, 7(10): 5281-5290

[5] EhteshamM, BlackKL, YuJS. Recent Progress in Immunotherapy for Malignant Glioma: Treatment Strategies and Results from Clinical Trials. Cancer Control, 2004, 11(3): 192-207

[6] YaoJ, CaballeroOL, YungWKA, et al.. Tumor subtype-specific cancer-testis antigens as potential biomarkers and immunotherapeutic targets for cancers. Cancer Immunol Res, 2014, 2(4): 371-379

[7] SalmaninejadA, ZamaniMR, PourvahediM, et al.. Cancer/Testis Antigens: Expression, Regulation, Tumor Invasion, and Use in Immunotherapy of Cancers. Immunol Invest, 2016, 45(7): 619-640

[8] FreitasM, MalheirosS, StávaleJN, et al.. Expression of Cancer/Testis Antigens is Correlated with Improved Survival in Glioblastoma. Oncotarget, 2013, 4(4): 636-646

[9] ShiL, ZhangQM, WeiZD, et al.. Expression Status and Prognostic Value of cancer/testis antigen OY-TES-1 in Glioma. Int J Clin Exp Pathol, 2016, 9(2): 1598-1607

[10] LiX, YanJ, FanR, et al.. Serum immunoreactivity of cancer/testis antigen OY-TES-1 and its tissues expression in glioma. Oncol Lett, 2017, 13(5): 3080-3086

[11] HeSJ, GuYY, YuL, et al.. High expression and frequently humoral immune response of melanoma-associated antigen D4 in glioma. Int J Clin Exp Pathol, 2014, 7(5): 2350-2360

[12] LeeSY, ObataY, YoshidaM, et al.. Immunomic analysis of human sarcoma. Proc Natl Acad Sci U S A, 2003, 100(5): 2651-2656

[13] ParkJH, SongMH, LeeCH, et al.. Expression of the human cancer/testis antigen NY-SAR-35 is activated by CpG island hypomethylation. Biotechnol Lett, 2011, 33(6): 1085-1091

[14] SongMH, KimYR, BaeJH, et al.. A cancer/testis antigen, NY-SAR-35, induces EpCAM, CD44, and CD133, and activates ERK in HEK293 cells. Biochem Biophys Res Commun, 2017, 484(2): 298-303

[15] SongMH, KimYR, LeeJW, et al.. Cancer/testis antigen NY-SAR-35 enhances cell proliferation, migration, and invasion. Int J Oncol, 2016, 48(2): 569-576

[16] SongM, KimY, BaeJ, et al.. Effect of cancer/testis antigen NYSAR35 on the proliferation, migration and invasion of cancer cells. Oncol Lett, 2017, 13(2): 784-790

[17] KomoriT. The 2016 WHO Classification of Tumours of the Central Nervous System: The Major Points of Revision. Neurol Med Chir (Tokyo), 2017, 57(7): 301-311

[18] ZhangQM, HeSJ, ShenN, et al.. Overexpression of MAGE-D4 in colorectal cancer is a potentially prognostic biomarker and immunotherapy target. Int J Clin Exp Pathol, 2014, 7(7): 3918-3927

[19] LuoB, YunX, FanR, et al.. Cancer testis antigen OY-TES-1 expression and serum immunogenicity in colorectal cancer: its relationship to clinicopathological parameters. Int J Clin Exp Pathol, 2013, 6(12): 2835-2845

[20] HanCP, LeeMY, TzengSL, et al.. Nuclear Receptor Interaction Protein (NRIP) expression assay using human tissue microarray and immunohistochemistry technology confirming nuclear localization. J Exp Clin Cancer Res, 2008, 27(1): 1-7

[21] FuJ, LuoB, GuoWW, et al.. Down-regulation of cancer/testis antigen OY-TES-1 attenuates malignant behaviors of hepatocellular carcinoma cells in vitro. Int J Clin Exp Pathol, 2015, 8(7): 7786-7797

[22] CenYY, GuoWW, LuoB, et al.. Knockdown of OY-TES-1 by RNAi causes cell cycle arrest and migration decrease in bone marrow-derived mesenchymal stem cells. Cell Biology International, 2012, 36(10): 917-922

[23] FabrícioF C, BlancK L, et al.. Concise Review: Cancer/Testis Antigens, Stem Cells, and Cancer. Stem Cells, 2010, 25(3): 707-711

[24] Ghafouri-FardS, ModarressiMH. Cancer-testis antigens: potential targets for cancer immunotherapy. Arch Iran Med, 2009, 12(4): 395-404

[25] SalmaninejadA, ZamaniMR, PourvahediM, et al.. Cancer/Testis Antigens: Expression, Regulation, Tumor Invasion, and Use in Immunotherapy of Cancers. Immunol Invest, 2016, 45(7): 619-640

[26] ScanlanMJ, SimpsonAJG, OldLJ. The cancer/testis genes: Review, standardization, and commentary. Cancer Immun, 2004, 4(1): 1

[27] KimYD, ParkHR, SongMH, et al.. Pattern of cancer/testis antigen expression in lung cancer patients. Int J Mol Med, 2012, 29(4): 656-662

[28] MalumbresM, BarbacidM. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer, 2009, 9(3): 153-166

[29] DulicV, LeesE, ReedS. Association of human cyclin E with a periodic G1-S phase protein kinase. Science, 1992, 257(5078): 1958-1961

[30] KoffA, GiordanoA, DesaiD, et al.. Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science, 1992, 257(5077): 1689-1694

[31] HindsPW, MittnachtS, DulicV, et al.. Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell, 1992, 70(6): 993-1006

[32] HatakeyamaM, BrillJA, FinkGR, et al.. Collaboration of G1 cyclins in the functional inactivation of the retinoblastoma protein. Genes Dev, 1994, 8(15): 1759-1771

[33] PinesJ, HunterT. Human cyclin A is adenovirus E1A-associated protein p60 and behaves differently from cyclin B. Nature, 1990, 346(6286): 760-763

[34] TsaiLH, HarlowE, MeyersonM. Meyerson, Isolation of the human cdk2 gene that encodes the cyclin A- and adenovirus E1A-associated p33 kinase. Nature, 1991, 353(6340): 174-177

[35] ElledgeSJ, RichmanR, HallFL, et al.. CDK2 encodes a 33-kDa cyclin A-associated protein kinase and is expressed before CDC2 in the cell cycle. Proc Natl Acad Sci USA, 1992, 89(7): 2907-2911

[36] CardosoMC, LeonhardtH, Nadal-GinardB. Reversal of terminal differentiation and control of DNA replication: cyclin A and Cdk2 specifically localize at subnuclear sites of DNA replication. Cell, 1993, 74(6): 979-992

[37] HeuvelSVD, HarlowE. Distinct roles for Cyclin-dependent kinases in cell cycle control. Science, 1994, 262(5142): 2050-2054

[38] IshimiY, Komamura-KohnoY, YouZY, et al.. Inhibition of Mcm4,6,7 Helicase Activity by Phosphorylation with Cyclin A/Cdk2. J Biol Chem, 2000, 275(21): 16235-16241

[39] Omar F, Zhengying W, Knudsen KE, et al. Nuclear targeting of cyclin-dependent kinase 2 reveals essential roles of cyclin-dependent kinase 2 localization and cyclin E in vitamin D-mediated growth inhibition. Endocrinology, 2010(3):896–908

[40] KawanaH, TamaruJI, TanakaT, et al.. Role of p27Kip1 and Cyclin-Dependent Kinase 2 in the Proliferation of Non-Small Cell Lung Cancer. Am J Pathol, 1998, 153(2): 505-513

[41] LiY, ZhangJ, GaoW, et al.. Insights on Structural Characteristics and Ligand Binding Mechanisms of CDK2. Int J Mol Sci, 2015, 16(12): 9314-9340

[42] AliS, HeathcoteDA, KrollSHB, et al.. The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity. Cancer Res, 2009, 69(15): 6208-6215

[43] ZouH, HenzelWJ, LiuX, et al.. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent. Cell, 1997, 90(3): 405-413

[44] NuezG, BenedictMA, HuY, et al.. Caspases: the proteases of the apoptotic pathway. Oncogene, 1998, 17(25): 3237-3245

[45] KimB, SrivastavaSK, KimSH. Caspase-9 as a therapeutic target for treating cancer. Expert Opin Ther Targets, 2015, 19(1): 113-127

[46] ZhouQ, LiaoH, HuoZ, et al.. Cancer/Testis Antigens Trigger Epithelial-Mesenchymal Transition and Genesis of Cancer Stem-Like Cells. Curr Pharm Des, 2015, 21(10): 1292-1300

[47] Yao D, Dai C, Peng S. Mechanism of the Mesenchymal-Epithelial Transition and Its Relationship with Metastatic Tumor Formation. 2011,9(12):1608–1620

[48] ParkJH, SongMH, LeeCH, et al.. Expression of the human cancer/testis antigen NY-SAR-35 is activated by CpG island hypomethylation. Biotechnol Lett, 2011, 33(6): 1085-1091